80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]王集紅,郭永明,劉歆,等.布地奈德混懸液霧化吸入在慢性阻塞性肺疾病急性加重期患者中的應(yīng)用[J].福建醫(yī)藥雜志,2023,45(02):12-15.
　WANG Jihong,GUO Yongming,LIU Xin,et al.Application of aerosol inhalation of budesonide suspension in acute exacerbation of chronic obstructive pulmonary disease[J].FUJIAN MEDICAL JOURNAL,2023,45(02):12-15.
點擊復(fù)制

布地奈德混懸液霧化吸入在慢性阻塞性肺疾病急性加重期患者中的應(yīng)用()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期數(shù):
2023年02期
頁碼:
12-15
欄目:
臨床研究
出版日期:
2023-04-15

文章信息/Info

Title:
Application of aerosol inhalation of budesonide suspension in acute exacerbation of chronic obstructive pulmonary disease
文章編號:
1002-2600(2023)02-0012-04
作者:
王集紅; 郭永明; 劉歆; 江發(fā)英; 張春輝; 張美泉; 陸君琴
福建醫(yī)科大學(xué)教學(xué)醫(yī)院 福建省老年醫(yī)院呼吸與危重癥醫(yī)學(xué)科（福州 350009）
Author(s):
WANG Jihong;  GUO Yongming;  LIU Xin;  JIANG Faying;  ZHANG Chunhui;  ZHANG Meiquan;  LU Junqin
Department of Respiratory and Critical Care Medicine, Fujian Provincial Geriatric Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350009, China
關(guān)鍵詞:
慢性阻塞性肺疾病急性加重期; 布地奈德; 不同劑量; 霧化吸入
Keywords:
AECOPD;  budesonide;  different doses;  atomized inhalation
分類號:
R563.1
文獻標(biāo)志碼:
B
摘要:
目的 探討不同劑量布地奈德霧化吸入治療慢性阻塞性肺疾病急性加重期（AECOPD）患者的臨床療效。方法 選取我院2020年6月至2021年12月收治的150例AECOPD患者，采用隨機數(shù)表法分為高劑量組和低劑量組各75例，高劑量組和低劑量組分別按6 mg/d劑量和3 mg/d劑量布地奈德霧化吸入，對比用藥前后兩組CAT評分、肺功能、血氣指標(biāo)、總有效率及不良反應(yīng)率的差別。結(jié)果 用藥后，高劑量組CAT評分為8.09分，低于低劑量組的9.71分（P<0.05）；高劑量組肺功能指標(biāo)FEV1為1.80 L、FEV1/FVC為66.32%、FEV1%預(yù)計值為62.77，均高于低劑量組的1.64 L、58.43%、57.99（均P<0.05）；高劑量組血氣指標(biāo)PO2為82.45 mm Hg，高于低劑量組的73.62 mm Hg（P<0.05）；PCO2為58.03 mm Hg，低于低劑量組的63.95 mm Hg（P<0.05）；高劑量組總有效率96.00%，高于低劑量組81.33%（P<0.05）；高劑量組不良反應(yīng)發(fā)生率（30.67%）與低劑量組（28.00%）比較的差異無統(tǒng)計學(xué)意義（P>0.05）。結(jié)論 高劑量布地奈德霧化吸入更有效改善 AECOPD 患者肺功能及缺氧狀態(tài)，療效更顯著，不良反應(yīng)率增加不明顯。
Abstract:
Objective To investigate the clinical effect of budesonide atomized inhalation suspension with different doses in the treatment of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Methods A total of 150 patients with AECOPD diagnosed and treated in our hospital from June 2020 to December 2021 were randomly divided into high dose group （75 cases） and low dose group （75 cases）. The high dose group and the low dose group were given respectively with the 6 mg daily dose and the 3 mg daily dose of budesonide aerosol inhalation. The changes of the CAT scores, lung function, blood gas indicators, total treatment effective rates and adverse reaction rate were compared between the two groups before and after treatment. Results After treatment, the CAT score of the high dose group (8.09) was lower than that of the low dose group (9.71), there was significant difference（P<0.05） between them; the lung function indexes FEV1, FEV1/FVC and FEV1% predicted of the high dose group (1.80 L, 66.32% and 62.77) were respectively higher than those of the low dose group (1.64 L, 58.43% and 57.99)，and there were significant differences （P<0.05） between them； the blood gas index PO2 of the high dose group (82.45 mm Hg) was higher than that of the low dose group (73.62 mm Hg), and the PCO2 of the high dose group (58.03 mm Hg) was lower than that of the low dose group (63.95 mm Hg), there were significant differences （P<0.05） between them； the total effective rate of the high dose group (96.00%) was higher than that of the low dose group (81.33%)，and there was significant difference （P<0.05） between them; there was no significant difference （P>0.05） between the adverse reaction rate of the high dose group (30.67%) and that of the low dose group (28.00%). Conclusion High dose of budesonide atomized inhalation suspension can effectively improve lung function and hypoxia in AECOPD patients, which has significant clinical effects,while the increase of adverse reaction rate is not obvious.

參考文獻/References:

[1] 戴思平,李芳華.無創(chuàng)呼吸機在已經(jīng)出現(xiàn)呼吸肌疲勞但不伴有呼吸衰竭的AECOPD患者中的應(yīng)用價值[J].臨床與病理雜志,2016,36（8）: 1156-1161.
[2] Vogelmeier C F,Criner G J,Martinez F J,et al.Global strategy for the diagnosis,management and prevention of chronic obstructive lung disease 2017 report GOLD executive summary [J].Am J Respir Crit Care Med,2017,195 （5）: 557-582.
[3] 慢性阻塞性肺疾病急性加重（AECOPD）診治專家組.慢性阻塞性肺疾病急性加重（AECOPD）診治中國專家共識（2017年更新版）[J].國際呼吸雜志,2017,37（14）: 1041-1057.
[4] 呼吸系統(tǒng)疾病基層診療指南編寫專家組.慢性阻塞性肺疾病基層診治指南（2018）[J].中華全科醫(yī)師雜志,2018,17（11）: 856-870.
[5] Qian W,Huang G Z.Neutrophil CD64 as a marker of bacterial infection in acute exacerbations of chronic obstructive pulmo-nary disease [J].Immunol Invest,2016,45:490-503.
[6] 阮偉良,陳勝海.霧化吸入較大劑量布地奈德治療COPD急性加重期的臨床觀察[J].浙江醫(yī)學(xué),2016,38（12）: 1026-1027.
[7] 王海平,溫娟瑩.糖皮質(zhì)激素類藥物在呼吸內(nèi)科中的用藥現(xiàn)狀及合理性評價[J].中國現(xiàn)代藥物應(yīng)用,2017,11（10）: 136-137.
[8] 陳亞紅.2017年GOLD慢性阻塞性肺疾病診斷、治療及預(yù)防的全球策略解讀[J].中國醫(yī)學(xué)前沿雜志（電子版）,2017,9（1）: 37-47.
[9] Ucar E Y,Araz O,Meral M,et al.Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: A randomized control trial[J].Med Sci Monit,2014,20: 513-520.
[10] Gunen H,Hacievliyagil S S,Yetkin O,et al.The role of nebulised budesonide in the treatment of exacerbations of COPD[J].Eur Respir J,2007,29（4）: 660-667.
[11] Maltais F,Ostinelli J,Bourbeau J,et al.Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial[J].Am J Respir Crit Care Med,2002,165（5）: 698-703.
[12] 楊爭光,王鵬軍.不同劑量布地奈德混懸液對COPD患者療效、激素抵抗性及安全性的影響[J].臨床醫(yī)學(xué)研究與實踐,2019,4（17）:13-15.
[13] 張蕊,陳碧,李元芹,等.霧化吸入不同劑量布地奈德在治療慢性阻塞性肺病急性加重期的療效[J].實用醫(yī)學(xué)雜志,2019,35（24）: 3827-3831.
[14] 中華醫(yī)學(xué)會臨床藥學(xué)分會《霧化吸入療法合理用藥專家共識》編寫組.霧化吸入療法合理用藥專家共識（2019年版）[J].醫(yī)藥導(dǎo)報,2019,38（2）: 135-146.
[15] 周雁蘋,鄭鎮(zhèn)波,周鶴銘,等.AECOPD患者采用不同劑量布地奈德霧化吸入治療的臨床療效[J].現(xiàn)代診斷與治療,2019,30（9）: 1521-1523.
[16] 戴凱麗,張薇,劉磊.吸入性糖皮質(zhì)激素在慢性阻塞性肺疾病應(yīng)用中的新進展[J].醫(yī)學(xué)綜述,2016,22（23）: 4645-4648.

相似文獻/References:

[1]許能鑾,鄭建獅,陳愉生,等.慢性阻塞性肺疾病急性加重期205例出院后1年內(nèi)死亡的相關(guān)因素分析[J].福建醫(yī)藥雜志,2022,44(01):18.
　XU Nengluan,ZHENG Jianshi,CHEN Yusheng,et al.Analysis of factors related to the death within one year after discharge in 205 patients with acute exacerbation of chronic obstructive pulmonary disease[J].FUJIAN MEDICAL JOURNAL,2022,44(02):18.

更新日期/Last Update: 2023-04-15